Spyre Therapeutics, Inc.

Spyre Therapeutics (SYRE) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, reflecting a stable filing record in our recent observation window. However, low signal in a 90-day window does not indicate absence of risk; the company's capital structure, financing history, and equity dilution trajectory require deeper analysis. The full $49 Report extends coverage to 12 months of SEC filings, calculates dilution risk scores, contextualizes all 8-K events, and flags emerging AI risk signals that may not yet appear in standard filings. The full $49 Report adds comprehensive dilution modeling, 12-month filing history, financing context, and AI risk assessment.